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Growth factors in ovarian cancer
O.J. Owens', C. Stewart2 & R.E. Leake'
'Department ofBiochemistry, Glasgow University, Glasgow G128QQ; and 2Department ofPathology, Glasgow Royal Infirmary,
Castle Street, Glasgow G4 OSF.
Summary Epidermal growth factor and transforming growth factor alpha are two peptides which bind to the
epidermal growth factor receptor. One hundred and seventy-four samples from 133 patients with ovarian
cancer were examined for EGF and TGFa. EGF was detected in only 27.6% of samples while TGFa was
present in 88.5%. The median values for TGFa presence were at least 10-fold greater than those of EGF.
There was no statistical difference between either TGFa or EGF levels and degree of differentiation of the
tumours. There was no statistical difference between stage three and four in relation to concentration of either
peptide. Median concentration did not differ significantly among the histological sub-groups.
Epidermal growth factor (EGF) interacts with its receptor,
epidermal growth factor receptor (EGFR), initiating the re-
sponses which can lead to growth modulation. Additionally
such ligand-receptor interaction induces pleiotropic effects in
the cell including enhanced glycolysis, increased amino acid
transport, calcium, sodium and hydrogen ion exchange and
protein synthesis (Owen et al., 1982). Another growth factor,
transforming growth factor alpha (TGFa) binds to the
EGFR. Sporn and Roberts (1985) have shown that transform-
ing growth factors are produced by a variety of malignant
cells.
The growth factor content of tumours has two potential
therapeutic implications. Firstly, tumours characterised by
stimulatory autocrine mechanisms or receptor abnormalities
are theoretically amenable to the use of receptor antagonists
or antibodies directed against either the growth factor or its
receptor. Secondly, if some tumours are found to have lost
the ability to secrete an autocrine inhibitory molecule, then
replacement of the inhibitor or use of a synthetic analogue
becomes feasible.
The aim of this study was to measure the quantity of both
EGF and TGF(x in tumour samples derived from patients
with epithelial ovarian cancer and where possible to compare
the peptide levels between degree of differentiation of the
tumours, stage of disease and histological sub-type of
tumour. As patient follow-up was not sufficiently long, no
effort was made to compare peptide levels with survival.
Materials and methods
Collection and storage of tumour specimens
One hundred and seventy-four ovarian tumour samples
obtained from 133 consecutive patients were collected fresh
from the operating theatre, snap frozen in liquid nitrogen
and stored at - 70°C or collected fresh and placed in sucrose
glycerol buffer (Crawford et al., 1984) at - 20°C until
assayed.
Extraction ofEGFand TGFx
Frozen tumour specimens were removed from storage and
allowed to thaw on ice. Once thawed the tumour specimen
was mopped with tissue paper to remove excess water. Speci-
mens stored in sucrose/glycerol buffer were thoroughly re-
hydrated in homogenisation buffer. Specimens were washed
in ice cold saline. The tumour was bisected and two separate
samples were cut from either half, one placed in formal saline
for pathological analysis and the other stored in sucrose/
glycerol buffer for later immunohistochemical analysis. Fresh
homogenising buffer was prepared (20 mM HEPES, 2 mM
EDTA and 0.5 mM PMSF adjusted to pH 7.4 with sodium
hydroxide) and stored on ice. The two tumour sections, from
which the samples for pathology had been removed (usually
1 g) were then cut into small 1 mm blocks, weighed and
placed in a centrifuge tube on ice. Homogenising buffer
(5 ml g-'wet weight) was added.
The tumour was homogenised on ice with an ultra turrax
(Janke & Kunkel) with 2 x 15 s bursts at maximum speed
but allowing the homogenate to cool between bursts. The
resulting homogenate was an even suspension devoid of
clumps of tumour tissue. The homogenate was centrifuged at
1,000 g for 10min. The resulting supematant was subjected
to a higher speed spin (12,000 g for 1 h). The nuclear pellet
from the first spin was resuspended in 3 ml of homogenising
buffer and stored at - 20°C until required for DNA analysis
(Modified Burton). The supernatant from the high speed spin
was added to two volumes of ice cold alcohol and this was
centrifuged at 1,000 g for 30 min. The supernatant from the
alcohol extraction was added to four volumes of ice cold
ethyl acetate and placed in a fridge overnight (4°C). After
16 h a crude extract precipitated to the bottom of the vessel.
The supernatant was discarded and the crude extract was
suspended in 2 ml of 1 N acetic acid. The extract was stored
at - 70°C until required for lyophilisation.
Lyophilisation
Extracts were removed from - 70C and the caps were
loosened or the nescofilm pierced. Sodium hydroxide pellets
were placed in the bottom of a 'dessicator' and the samples
placed above on a metal shelf. The dessicator was attached to
a pump (Javac Double Stage high Vacuum Pump ID 60)
through an ice cooled trap. The pump was switched on and
the lyophilisation usually took place over 16 h. The
lyophilised product was resuspended in 1 ml of RIA buffer
(0.2 M Na2HPO4, 0.2 M NaH2PO4, 0.1% Sodium Azide,
0.15 M Sodium Chloride, 0.01 M EDTA, 0.5% BSA and pH
to 7.4) and placed on ice or stored dry at - 20°C.
Radioimmunoassayfor EGFand TGFo
Lyophilised tumour extracts were removed from - 200C and
thawed on ice. Each extract was resuspended in 1 ml of RIA
buffer and placed on ice. Standards were earlier prepared in
RIA buffer using human recombinant EGF or TGFa (in
RIA buffer) as supplied by Imperial Chemical Industries
(ICI) and the actual values on the standard curve were as
follows: 0, 20 pg, 50 pg, 100 pg, 250 pg, 500 pg, 750 pg, 1 ng,
5 ng and lO ng.
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Table I Patient and tumour characteristics
Serous Endometrioid Mucinous Clear cell Undifferentiated
Patients 80 19 12 9 13
Samples 109 20 12 14 19
Mean age 59.7 61.2 62.2 58.9 62.3
Age range 25-88 43-82 45-83 52-71 42-72
TGFax
% positive 84.4 95 100 85.7 100
Range 0.041-33 0.08-83.2 0.239 x 3.53 0.092-55.7 0.071-5.43
Median 1.178 1.338 1.68 1.235 0.387
EGF
% positive 26.6 45 25 35.7 10.5
Range 0.022-0.582 0.045-0.505 0.062-0.18 0.073-1.54 0.075 + 0.122
Median 0.104 0.166 0.151 0.423
The table shows the median value and range for both TGFa and EGF in relation to histological
sub-groups.
Antibody dilutions were made up fresh with RIA buffer in
the range of 1:10,000-1:20,000 for TGFa and usually
1:100,000 for EGF but these dilutions varied slightly from
one iodination to the next. The antibody was placed on ice.
Antibodies (sheep polyclonal) were supplied from ICI
Pharmaceuticals as a gift.
Iodination of peptides (EGF, TGFa were human recom-
binant) was performed as a modification of Gregory et al.
(1988) by an 'in-house' technique using iodogen and a col-
umn containing Biogel P6. Free iodine (125) was purchased
from NEN. The iodinated peptide came off the first peak of
the column and the fraction with the maximum on competi-
tion assay was used for the radioimmunoassay. Finally the
labelled peptides were made up with RIA buffer to give
30,000 c.p.m./250fil. For every 1 ml of labelled peptide 4ttl
of sheep serum was added to reduce non-specific binding.
Tumour extract (250 ilI) was added in duplicate to eppen-
dorfs. The primary antibody (either anti EGF or TGFa) was
added to each eppendorf in a volume of 250 lAl. Finally
250 il of I12' EGF was added to the eppendorfs in which the
primary antibody was anti EGF and 1125 TGFa when the
antibody was anti TGFa. The eppendorfs were capped,
gently vortexed and incubated at 4°C for 48 h. The standards
were treated in the same way.
Secondary antibody (donkey/antisheep - Scottish antibody
production unit) at a dilution of 1:15 (made up in RIA
buffer) in a volume of 250 LI was added to unknowns and
standards. Incubation continued for a further 24 h at 4°C.
All specimens were centrifuged at 40,000g in a refrigerated
centrifuge (Sarstedt) for 20 min. The supernatant was
removed with a pasteur attached to a water pump and the
pellet remaining was counted on a Thorn EMI 620 Turbo
multichannel gamma counter (60% efficiency). The peptide
content was read off the standard curve.
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Figure 1 TGFa levels in relation to degree of differentiation. In
the WD group one value of 55.7 ngmg' DNA is not included
on the graph, while in the MD group two values of 27 and
33 ng mg1 DNA are excluded. In the PD group there was one
sample of 83.17 ng mg' DNA.
Statistical analysis
Chi-square testing was used for statistical analysis.
Results
Placental tissue and efficiency ofextraction
Initial experiments using placental tissue showed that there
was no difference in the levels of EGF and TGFX measured
whether tissue was stored at
- 20°C in sucrose/glycerol
buffer or snap frozen in liquid nitrogen and stored at
- 70°C. The efficiency of extraction for these peptides was
calculated to be 60% when placenta was spiked with known
amounts of EGF or TGFa. Peptides were expressed in
ng mg-' DNA. The assay performed for TGFx and EGF
was sensitive over the range of 20 pg to 10 ng ml-' and there
was no cross reactivity between TGFax and EGF.
Type oftumour andstage
The results were grouped and analysed depending on the
histological type of tumour (Serov et al., 1973). These were
all common epithelial tumours which comprised serous,
endometrioid, mucinous, clear cell and undifferentiated sub-
types. All patients were staged in accordance with the revised
FIGO staging for ovarian cancer (Shepherd, 1989). Stage 1
and 2 were subdivided into a, b and c. It was not possible to
divide Stage 3 into the various substages.
Tumour results
Table I illustrates the breakdown of results overall for 133
patients and 174 samples. The mean age is fairly similar
among the groups. In fact only 11.5% of samples were
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Figure 2 EGF levels and degree of differentiation of tumours.
The MD group has one value of 1.536 ng mg- I DNA not
included while the PD group also has one sample of
1.029 ngmg-1 DNA.
la 1b lc 2a 2b 2c 3 4
Stage
Figure 4 EGF and stage of disease. The following values are not
included on the graph: Stage 2b, 1.029 ng mg'I DNA and Stage
4, 1.536ngmg' DNA.
15
14
13
12
11
10
z
E
CD
U-
(9
I..
I..
.I . .
:.. ... .... -t
....I;.. .::...
1a 1b ic 2a b
Stage
2c 3 4
9
8
7'-
6-
5.-
4-
3-
2'
1 -
0
S-Serous
E-Endometrioid
U-Undifferentiated
C-Clear Cell
M-Mucinous
. I
. I .
:p .
*.11
S E U C M
Figure 3 TGFa and stage of disease. The following stages have
values excluded from the graph: Stage la, 83.17 ng mg' DNA,
Stage 2b, 55.7 ng mg'I DNA, Stage 3, 27 ng mg'I DNA and
Stage 4, 33 ng mg-' DNA.
Figure 5 TGFa and histological type of tumour. The following
values have not been included on the graph: Serous, 27 and
33 ng mg DNA, endometrioid 83.17 ng mg-I DNA and clear cell
55.7 ng mg-' DNA.
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negative for TGFa and the median values were similar except
for the undifferentiated group. EGF was absent in 72.4% of
samples and apart from the clear cell group the median
values were similar.
Figures 1 to 6 show the distribution of results as follows:
Figure 1 divides the TGFax values into well differentiated
(range 0.124-55.7 ng mg'l DNA, median 1.290), moderately
differentiated (range 0.041-33 ng mg' DNA, median) and
poorly differentiated (range 0.090-83.17 ng mg- DNA,
median 0.723). The majority of values falling under
2ngmg-' DNA. There is no statistical difference between
these results. Figure 2 refers to EGF values and differentiation.
The well differentiated group (range 0.022-0.505 ngmg-'
DNA, median 0.166) contained the smallest number of sam-
ples, moderately differentiated (range 0.023-1.536 ng mg-'
DNA, median 0.199) had the greatest number while the
poorly differentiated had less (range 0.042-1.029 ngmg-'
DNA, median 0.075). Again there was no significance among
these groups. Figure 3 subdivides TGFa into different stages.
The majority of samples are Stage 3 and 4. The median
values are 3.527 ngmg' DNA for Stages la, 0.789 ng mg'
DNA for Stage lb and 1.496 for Stage Ic. There is only one
value for Stage 2a while the median for Stage 2b is 1.052 and
2.310 for Stage 2c. Stage 3 has a median of 1.492 ngmg'
DNA while Stage 4 has a median of 0.960 ng mg' DNA.
There is no significant difference between Stage 3 and 4 while
the other stages are too small to apply statistics. Figure 4 has
the results for EGF and stage and the medians are as fol-
lows: Stage la, 0.085; Stage Ic, 0.166; Stage 2b, 0.423; Stage
3, 0.122 and Stage 4, 0.075 ngmg-' DNA. Again the results
are too small to apply statistics. Figure 5 relates TGFa levels
to the various types of tumour. The median values are:
serous 1.178 ng mg' DNA, endometrioid 1.338 ngmg'
DNA, undifferentiated 0.387 ngmg' DNA, clear cell
1.235 ngmg' DNA and mucinous 1.68 ngmg' DNA.
Finally, Figure 6 relates EGF median values for the different
tumour types which are as follows: serous 0.097 ngmg-'
DNA, endometrioid 0.166 ngmg' DNA, undifferentiated
0.0985 ngmg-' DNA, clear cell 0.423 ngmg'I DNA and
mucinous 0.151 ngmg-' DNA.
Discussion
TGFa was present in 88.5% of samples compared to EGF
which was present in only 27.6% of samples. The range of
TGFa overall is vast but the majority of values lie below
5 ngmg-' DNA. EGF was rarely present above 0.3 ngmg-'
DNA and there was a 10-fold difference at least between the
median values ofTGFa compared to EGF. We could find no
statistical difference between degree of differentiation of the
tumour and TGFa or EGF values. Concentration of TGFa
or EGF, in relation to patient follow-up will be assessed at a
later date.
Kohler et al. (1989) looked at EGF-like factors in ovarian
and cervical cancers. They found that 30% of tumour ex-
tracts contained higher EGF-like factors (EGF-F
4-15 ngmg-') than those found in non-malignant speci-
mens. They also found that in ovarian carcinoma patients
with high EGF-F levels had a poor prognosis. Arteaga et al.
(1988) found that 42% of ovarian cancers contained
immunoreactive TGFa activity. They also state that this
TGFx correlated with patient performance status (PS) and
tumour burden. Bauknecht et al. (1986) found EGF-like
factors (probably TGFx) in ovarian tumours. They
specifically noted that in epidermal growth factor receptor
(EGFR) positive carcinomas the EGF-like factors ranged
between 0 and 9 ng EGF units mg-' protein, while in the
EGFR negative group the EGF-like factors ranged between 0
and 19.3 ng EGF unitsmg' protein. We have not compared
peptide levels as yet between samples which are EGFR
positive or negative.
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Figure 6 EGF and histological type of tumour. The following
values have been excluded from the graph: Clear cell, 1.029 and
1.536 ng-'mg DNA.
Hanauske et al. (1988) looked at TGFa in effusions from
cancer patients using a rat TGFa raised in sheep against the
C-terminal 17 amino acids. The lower limit of detection was
only 1.56 ng ml-'. They found TGFx activity more fre-
quently in effusions from cancer patients than controls.
Others have found TGFa-like substances in the urine of
cancer patients. However, the assays for TGFa were not
specific and would have detected other EGF-related growth
factors (Twardzik et al., 1982; Sherwin et al., 1983; Kimball
et al., 1984). TGFa is found in effusions even in the absence
of positive cytology. We also found TGFa in ascitic fluid
(Owens, MD thesis, 1990) with positive cytology and also in
fluid where tumour cells were absent (benign cysts and free
fluid). Arteaga et al. (1988) and Stromberg et al. (1987)
suggest that TGFa levels in the serous effusions from cancer
patients are a reliable index for tumour burden and overall
patient survival. It is interesting that Hanauske et al. (1988)
state that the TGFa activity is not characteristic of any single
tumour type as they were unable to detect any difference
between breast, ovary and lung primaries.
In conclusion TGFa was present in a greater proportion of
patients and also in larger quantities compared to EGF.
Neither peptide appears to show any significant difference in
levels with regard to stage, differentiation or type of tumour.
It is hoped that when follow-up is sufficiently long that we
may be able to compare TGFa and EGF with survival and
death.
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